.
New Delhi, April 26 (MondayMirror.com) The Drugs Controller General of India (DCGI) on Tuesday approved the restricted emergency use authorisation (EUA) to Bharat Biotech’s Covaxin for children between the age of 6-12 years, sources said.
The DGCI has asked vaccine manufacturer to submit safety data including the data on adverse event with due analysis every 15 days for the first two months and monthly thereafter upto 5 months, said the source familiar with the development.
This development comes after the Subject Expert Committee (SEC) discussed recommendations for the restricted emergency use of Covaxin in children aged between 2-12 years.
However, the SEC, after a meeting on Thursday, had recommended restricted emergency use of Biological E’s Covid-19 vaccine, Corbevax, in children aged 5-12 years.
Source: IANS
Rohtak The second convocation ceremony of Dada Lakhmi Chand State University of Performing and…
Rotarian and financial expert Nitin Kapur has authored ‘Gullak – Practical Mantras for Financial Planning,’…
Corrugated box manufacturers in India have expressed serious concern over rising costs, calling it an…
In a heartfelt celebration of resilience, courage and silent achievement, the ‘Ageless Women Soirée’ brought…
BJP leader Akshay Sharma flags off free pilgrimage from Ward 62 to Khatu Shyam and…
On the occasion of International Noise Awareness Day, an awareness campaign titled “Dhwani The Peace”…